PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • ID: 4051425
  • Report
  • Region: Global
  • 433 pages
  • GlobalData
1 of 6
Schizophrenia Treatment Urgently Requires Drugs Targeting Negative Symptoms

FEATURED COMPANIES

  • Alexza Pharmaceuticals
  • AstraZeneca
  • Eli Lilly
  • Indivior
  • Merck & Co.
  • Novartis
  • MORE
Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including attention, memory, and executive functions).

The pharmaceutical sales for schizophrenia were approximately US$6.4 Billion throughout the 7MM in 2015. The US contributed to 77.0% of these sales, generating US$4.9 Billion, driven predominantly by sales of atypical antipsychotics. With sales of approximately US$1.0 Billion, Otsuka/Bristol-Myers Squibb’s (BMS’s) Abilify (aripiprazole) accounted for 21.1% of all US sales in 2015.

Global schizophrenia sales are expected to grow to US$7.3 Billion by 2025, at a Compound Annual Growth Rate (CAGR) of 1.4%. The US is set to retain market share over the 10-year forecast period and contribute to 77.2% of sales by 2025, generating approximately US$5.6 Billion.

As per Christos Michaelides, Analyst, “While schizophrenia market growth will primarily be driven by the arrival of late-stage pipeline products, such as Minerva’s MIN-101 and Intra-Cellular Therapies’ ITI-007, both of which are directed towards the treatment of negative symptoms associated with schizophrenia, these symptoms will remain a significant unmet need in the space.

Major drivers of growth of the schizophrenia market during the forecast period include:
- The uptake of novel pipeline products that have been designed to satisfy unmet needs in the disease.
- Development of long-acting injectable (LAI) formulations of atypical antipsychotics in order to improve patient compliance, a notable unmet need.

The report “PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025” provides an overview of schizophrenia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Moreover, this report provides the following analysis:
- Provides Annualized schizophrenia market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Covers market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the schizophrenia therapeutics market.
- Pipeline analysis: focus on nine late-stage pipeline schizophrenia drugs, discussing emerging trends as well as an overview of earlier phase drugs.
- Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Companies mentioned in this report: Alexza Pharmaceuticals, Alkermes, Allergan, Almirall Prodesfarma, Astellas, AstraZeneca, Avanir Pharmaceuticals, Avineuro Pharmaceuticals, Braeburn Pharmaceuticals, Bristol-Myers Squibb, Dainippon Sumitomo/Sunovion, Eli Lilly, Epomedics, Ferrer, Gedeon Richter, HLS Therapeutics, Indivior, Intra-Cellular Therapies, Janssen, Laboratorios Farmaceuticos Rovi, Lundbeck, Meiji Seika, Merck & Co., Minerva Neurosciences, Mitsubishi Tanabe Pharma, Neurocrine Biosciences, Nitto Denko Corporation, Novartis, Otsuka, Pfizer, Sandoz, Sanofi, SyneuRx, Takeda, Teva Pharmaceutical, Titan Pharmaceutical, Vanda Pharmaceuticals, Yoshitomi Yakuhin Corporation.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Alexza Pharmaceuticals
  • AstraZeneca
  • Eli Lilly
  • Indivior
  • Merck & Co.
  • Novartis
  • MORE
1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification

3.3 Symptoms

3.4 Course

3.5 Prognosis

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global Trends

4.3.1 US

4.3.2 5EU

4.3.3 Japan

4.4 Forecast Methodology

4.4.1 Sources Used

4.4.2 Forecast Assumptions and Methods

4.4.3 Sources Not Used

4.5 Epidemiological Forecast for Schizophrenia (2015-2025)

4.5.1 12-Month Diagnosed Prevalent Cases of Schizophrenia

4.5.2 Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia

4.5.3 Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia

4.5.4 Age-Standardized 12-Month Diagnosed Prevalence of Schizophrenia

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 Limitations of the Analysis

4.6.3 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis Overview

5.1.1 Clinical Evaluation

5.2 Treatment Overview

5.2.1 Treatment Initiation

5.2.2 Maintenance Treatment

5.2.3 Treatment of Breakthrough Episodes

5.2.4 Long-Acting Injectables

5.2.5 Treatment-Resistance

5.2.6 Acute Agitation

5.2.7 Adjunctive Psychotherapy

5.3 Treatment Guidelines and Leading Prescribed Drugs

5.4 US

5.5 5EU

5.6 Japan

6 Competitive Assessment

6.1 Overview

6.2 Product Profiles - Atypical Antipsychotics

6.2.1 Abilify (aripiprazole)

6.2.2 Aristada (aripiprazole lauroxil)

6.2.3 Clozapine (widely genericized)

6.2.4 Fanapt (iloperidone)

6.2.5 Geodon (ziprasidone)

6.2.6 Invega (paliperidone)

6.2.7 Latuda (lurasidone)

6.2.8 Lonasen (blonanserin)

6.2.9 Rexulti (brexpiprazole)

6.2.10 Risperdal (risperidone)

6.2.11 Saphris (asenapine)

6.2.12 Seroquel (quetiapine)

6.2.13 Vraylar (cariprazine)

6.2.14 Zyprexa (olanzapine)

6.3 Product Profiles - Typical Antipsychotics

6.3.1 Typical Antipsychotics

6.3.2 Adasuve (Staccato loxapine)

6.4 Other Therapeutic Classes

7 Unmet Needs and Opportunities

7.1 Overview

7.2 Development of Cognitive-Enhancing Drugs

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Development of Drugs to Treat Negative Symptoms

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Improved Treatment Options for Treatment-Resistant Patients

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Development of Drugs with Enhanced Safety Profiles

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 Development of Drugs to Increase Compliance

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

8 Pipeline Assessment

8.1 Overview

8.1.1 Clinical Trials by Class of Therapy

8.2 Promising Drugs in Clinical Development

8.2.1 ALKS-3831

8.2.2 ITI-007

8.2.3 Lu AF35700

8.2.4 MIN-101

8.2.5 Risperidone implant

8.2.6 Risperidone ISM

8.2.7 RBP-7000

8.2.8 AVN-211

8.2.9 NaBen

8.3 Other Drugs in Development

9 Current and Future Players

9.1 Overview

9.2 Trends in Corporate Strategy

9.3 Company Profiles

9.3.1 Alkermes

9.3.2 Dainippon Sumitomo

9.3.3 Eli Lilly

9.3.4 Intra-Cellular Therapies

9.3.5 Janssen

9.3.6 Lundbeck

9.3.7 Minerva Neurosciences

9.3.8 Otsuka

10 Market Outlook

10.1 Global Markets

10.1.1 Forecast

10.1.2 Drivers and Barriers - Global Issues

10.2 US

10.2.1 Forecast

10.2.2 Key Events

10.2.3 Drivers and Barriers

10.3 5EU

10.3.1 Forecast

10.3.2 Key Events

10.3.3 Drivers and Barriers

10.4 Japan

10.4.1 Forecast

10.4.2 Key Events

10.4.3 Drivers and Barriers

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Diagnosed Schizophrenia Patients

11.4.2 Percent Drug-Treated Patients

11.4.3 Launch and Patent Expiry Dates

11.4.4 General Pricing Assumptions

11.4.5 Individual Drug Assumptions

11.4.6 Generic Erosion

11.4.7 Pricing of Pipeline Agents

11.5 Primary Research - KOLs Interviewed for this Report

11.6 Primary Research - Prescriber Survey

11.7 About the Authors

11.7.1 Analyst

11.7.2 Therapy Area Director

11.7.3 Epidemiologist

11.7.4 Managing Epidemiologist

11.7.5 Global Director of Therapy Analysis and Epidemiology

11.8 About

11.9 Disclaimer

1.1 List of Tables

Table 1: DSM-V Schizophrenia Specifiers

Table 2: Classification of Schizophrenia According to DSM-IV and ICD-10

Table 3: Other Schizophrenia Spectrum Disorders, 2015

Table 4: Symptoms of Schizophrenia

Table 5: Risk Factors and Comorbidities for Schizophrenia

Table 6: 7MM, Sources of 12-Month Diagnosed Prevalence Data

Table 7: 7MM, 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages =13 Years, Both Sexes, N, Select Years, 2015-2025

Table 8: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages =13 Years, Both Sexes, N (Row %), 2015

Table 9: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages =13 Years, N (Row %), 2015

Table 10: Treatment Guidelines for Schizophrenia

Table 11: Most Prescribed Drugs for Schizophrenia in the 7MM, 2015

Table 12: Country Profile - US

Table 13: Country Profile - 5EU

Table 14: Country Profile - Japan

Table 15: Leading Treatments for Schizophrenia, 2015

Table 16: Product Profile - Abilify

Table 17: Efficacy Results for Abilify in Schizophrenia Trials

Table 18: Efficacy Results for Abilify in Schizophrenia Trials

Table 19: AEs at =2% Incidence in Schizophrenia and Bipolar I Disorder Trials of Abilify

Table 20: AEs at =2% Incidence in a Schizophrenia Trial of Abilify Maintena

Table 21: Abilify SWOT Analysis, 2016

Table 22: Product Profile - Aristada

Table 23: Efficacy Results for Aristada in Schizophrenia Trial

Table 24: AEs at =2% Incidence in a Schizophrenia Trial of Aristada

Table 25: Aristada SWOT Analysis, 2016

Table 26: Product Profile - Clozapine

Table 27: Efficacy Results for Clozapine in Treatment-Resistant Schizophrenia Patients

Table 28: AEs at =5% Incidence in a Short-Term Trial of Clozapine

Table 29: AEs at =2% Incidence in All Clinical Trials of Clozapine (Excluding InterSePT)

Table 30: AEs at =10% Incidence During the InterSePT Trial of Clozapine

Table 31: Clozapine SWOT Analysis, 2016

Table 32: Product Profile - Fanapt

Table 33: AEs at =2% Incidence in Short-Term Trials of Fanapt

Table 34: Fanapt SWOT Analysis, 2016

Table 35: Product Profile - Geodon

Table 36: AEs at =2% Incidence in Schizophrenia Trials of Geodon

Table 37: Geodon SWOT Analysis, 2016

Table 38: Product Profile - Invega

Table 39: Efficacy of Invega Sustenna in Adult Schizophrenia Short-Term Trials

Table 40: AEs at =2% Incidence in Adult Schizophrenia Trials of Invega

Table 41: AEs at =2% Incidence in an Adolescent Schizophrenia Trial of Invega

Table 42: AEs at =2% Incidence in Schizophrenia Trials of Invega Sustenna

Table 43: AEs at =2% Incidence in a Long-Term Maintenance Trial of Invega Trinza in Schizophrenic Patients

Table 44: Invega SWOT Analysis, 2016

Table 45: Product Profile - Latuda

Table 46: Efficacy Results for Latuda in Schizophrenia Trials

Table 47: AEs at =2% Incidence in Schizophrenia Trials of Latuda

Table 48: Latuda SWOT Analysis, 2016

Table 49: Product Profile - Lonasen

Table 50: Efficacy Results for Lonasen in Haloperidol-Controlled Clinical Trial

Table 51: Efficacy Results for Lonasen in Risperidone-Controlled Clinical Trial

Table 52: AEs at =5% Incidence in a Short-Term Trial of Lonasen

Table 53: Lonasen SWOT Analysis, 2016

Table 54: Product Profile - Rexulti

Table 55: Efficacy Results for Rexulti in Short-Term Schizophrenia Trials

Table 56: AEs at =2% Incidence in Schizophrenia Trials of Rexulti

Table 57: Rexulti SWOT Analysis, 2016

Table 58: Product Profile - Risperdal

Table 59: Efficacy Results for Risperdal Consta in a 12-Week Schizophrenia Study

Table 60: AEs at =2% Incidence in Adult Schizophrenia Trials of Risperdal

Table 61: AEs at =5% Incidence in a Pediatric Schizophrenia Trial of Risperdal

Table 62: AEs at =5% Incidence in an Adult Schizophrenia Trial of Risperdal Consta

Table 63: Risperdal SWOT Analysis, 2016

Table 64: Product Profile - Saphris

Table 65: Efficacy Results for Saphris in Short-Term Schizophrenia Trials

Table 66: AEs at =2% Incidence in Schizophrenia Trials of Saphris

Table 67: Saphris SWOT Analysis, 2016

Table 68: Product Profile - Seroquel

Table 69: Efficacy Results for Seroquel in a Six-Week Schizophrenia Study

Table 70: Efficacy Results for Seroquel in Short-Term Schizophrenia Studies

Table 71: Efficacy Results for Seroquel XR in Schizophrenia Trials

Table 72: AEs at =2% Incidence in Adult Schizophrenia and Bipolar Mania Trials of Seroquel

Table 73: AEs at =2% Incidence in a Short-Term Trial of Seroquel in Schizophrenic Adolescents

Table 74: AEs at =2% Incidence in Six-Week Trials of Seroquel XR in Schizophrenic Adults

Table 75: Seroquel SWOT Analysis, 2016

Table 76: Product Profile - Vraylar

Table 77: Efficacy Results for Vraylar in a Six-Week Schizophrenia Study

Table 78: Efficacy Results for Vraylar in Short-Term Schizophrenia Studies

Table 79: AEs at =2% Incidence in Short-Term Schizophrenia Trials of Vraylar

Table 80: Vraylar SWOT Analysis, 2016

Table 81: Product Profile - Zyprexa

Table 82: AEs at =5% Incidence in Adult Schizophrenia Trials of Zyprexa

Table 83: AEs at =2% Incidence in Short-Term Trials of Zyprexa

Table 84: AEs at =1% Incidence in Adult Schizophrenia Trials of Zyprexa IntraMusular

Table 85: AEs at =5% Incidence in Adolescent Schizophrenia Trials of Zyprexa

Table 86: AEs Reported at =2% Incidence in a Schizophrenia Trial of Zyprexa Relprevv

Table 87: Zyprexa SWOT Analysis, 2016

Table 88: Typical antipsychotics SWOT Analysis, 2016

Table 89: Product Profile - Adasuve

Table 90: Efficacy Results for Adasuve in Agitation Trial of Schizophrenia Patients

Table 91: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve

Table 92: Adasuve SWOT Analysis, 2016

Table 93: Summary of Minor Therapeutic Classes, 2015

Table 94: Unmet Need and Opportunity in Schizophrenia

Table 95: Product Profile - ALKS-3831

Table 96: ALKS-3831 SWOT Analysis, 2016

Table 97: Product Profile - ITI-007

Table 98: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial

Table 99: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007

Table 100: ITI-007 SWOT Analysis, 2016

Table 101: Product Profile - Lu AF35700

Table 102: Lu AF35700 SWOT Analysis, 2016

Table 103: Product Profile - MIN-101

Table 104: Efficacy Results for MIN-101 in a 12-Week Phase IIb Schizophrenia Study

Table 105: Safety Evaluation of MIN-101 Phase IIa Clinical Trial in Schizophrenia

Table 106: AEs at =5% Incidence in a Phase IIb Schizophrenia Trial of MIN-101

Table 107: Safety Evaluation of MIN-101 Phase IIb Clinical Trial in Schizophrenia

Table 108: MIN-101 SWOT Analysis, 2016

Table 109: Product Profile - Risperidone Implant

Table 110: Risperidone Implant SWOT Analysis, 2016

Table 111: Product Profile - Risperidone ISM

Table 112: Risperidone ISM SWOT Analysis, 2016

Table 113: Product Profile - RBP-7000

Table 114: Efficacy Results for RBP-7000 in a Phase III Schizophrenia Trial

Table 115: AEs reported in a Phase III Schizophrenia Trial of RBP-7000A

Table 116: RBP-7000 SWOT Analysis, 2016

Table 117: Product Profile - AVN-211

Table 118: Attention tests and measures evaluated in a Phase IIa Schizophrenia Trial of AVN-211

Table 119: Psychometric Results in a Phase IIa Schizophrenia Trial of AVN-211

Table 120: Results of the Attention Measures that Showed Significant Changes in a Phase IIa Schizophrenia Trial of AVN-211

Table 121: AVN-211 SWOT Analysis, 2016

Table 122: Product Profile - NaBen

Table 123: PANSS Clinical Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia

Table 124: Other Clinical Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia

Table 125: Cognitive Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia

Table 126: NaBen SWOT Analysis, 2016

Table 127: Drugs in Development for Schizophrenia, 2015

Table 128: Key Companies in the Schizophrenia Market in the 7MM, 2015

Table 129: Alkermes’ Schizophrenia Portfolio Assessment, 2015

Table 130: Alkermes SWOT Analysis in Schizophrenia, 2015-2025

Table 131: Dainippon Sumitomo’s Schizophrenia Portfolio Assessment, 2015

Table 132: Dainippon Sumitomo SWOT Analysis in Schizophrenia, 2015-2025

Table 133: Eli Lilly’s Schizophrenia Portfolio Assessment, 2015

Table 134: Eli Lilly SWOT Analysis in Schizophrenia, 2015-2025

Table 135: Intra-Cellular Therapies’ Schizophrenia Portfolio Assessment, 2015

Table 136: Intra-Cellular Therapies SWOT Analysis in Schizophrenia, 2015-2025

Table 137: Janssen’s Schizophrenia Portfolio Assessment, 2015

Table 138: Janssen SWOT Analysis in Schizophrenia, 2015-2025

Table 139: Lundbeck’s Schizophrenia Portfolio Assessment, 2015

Table 140: Lundbeck SWOT Analysis in Schizophrenia, 2015-2025

Table 141: Minerva Neurosciences’ Schizophrenia Portfolio Assessment, 2015

Table 142: Minerva Neurosciences SWOT Analysis in Schizophrenia, 2015-2025

Table 143: Otsuka’s Schizophrenia Portfolio Assessment, 2015

Table 144: Otsuka SWOT Analysis in Schizophrenia, 2015-2025

Table 145: Schizophrenia Market - Drivers and Barriers, 2015-2025

Table 146: Key Events Impacting Sales for Schizophrenia in the US, 2015-2025

Table 147: Schizophrenia Market in the US - Drivers and Barriers, 2015-2025

Table 148: Key Events Impacting Sales for Schizophrenia in the 5EU, 2015-2025

Table 149: Schizophrenia Market in the 5EU - Drivers and Barriers, 2015-2025

Table 150: Key Events Impacting Sales for Schizophrenia in Japan, 2015-2025

Table 151: Schizophrenia Market in Japan - Drivers and Barriers, 2015-2025

Table 152: Key Launch Dates

Table 153: Key Patent/Exclusivity Expiries

Table 154: High-Prescribing Psychiatrists (Non-KOLs) Surveyed, By Country

1.2 List of Figures

Figure 1: Longitudinal Course of Schizophrenia

Figure 2: 7MM, 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages =13 Years, Both Sexes, N, Select Years, 2015-2025

Figure 3: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages =13 Years, Both Sexes, N, 2015

Figure 4: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages =13 Years, N, 2015

Figure 5: 7MM, Age-Standardized 12-Month Diagnosed Prevalence of Schizophrenia (Cases per 100,000 Population), Ages =13 Years, Both Sexes, 2015

Figure 6: Schizophrenia Therapeutics - Class of Therapy, 2016

Figure 7: Schizophrenia - Promising Late-Stage Phase IIb-III Pipeline Drugs, 2016

Figure 8: Competitive Assessment of Promising Late-Stage Pipeline Agents in Schizophrenia, 2015-2025

Figure 9: Clinical and Commercial Positioning of ALKS-3831

Figure 10: Clinical and Commercial Positioning of ITI-007

Figure 11: Clinical and Commercial Positioning of Lu AF35700

Figure 12: Clinical and Commercial Positioning of MIN-101

Figure 13: Clinical and Commercial Positioning of the Risperidone Implant

Figure 14: Clinical and Commercial Positioning of Risperidone ISM

Figure 15: Clinical and Commercial Positioning of RBP-7000

Figure 16: Clinical and Commercial Positioning of AVN-211

Figure 17: Clinical and Commercial Positioning of NaBen

Figure 18: Global Sales of Products for Schizophrenia by Company, 2015-2025

Figure 19: Company Portfolio Gap Analysis in Schizophrenia, 2015-2025

Figure 20: Global Sales for Schizophrenia by Region, 2015-2025

Figure 21: Global Sales for Schizophrenia by Drug Class, 2015-2025

Figure 22: Sales for Schizophrenia in the US by Drug Class, 2015-2025

Figure 23: Sales for Schizophrenia in the 5EU by Drug Class, 2015-2025

Figure 24: Sales for Schizophrenia in Japan by Drug Class, 2015-2025
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Alexza Pharmaceuticals
  • AstraZeneca
  • Eli Lilly
  • Indivior
  • Merck & Co.
  • Novartis
  • MORE
Schizophrenia treatment urgently requires drugs targeting negative symptoms.

The schizophrenia market across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to rise from $6.4 billion in 2015 to $7.3 billion by 2025, registering a compound annual growth rate of 1.4%, according to the research.

The company’s latest report states that major drivers of this modest growth include the uptake of novel pipeline products that have been designed to satisfy unmet needs in the disease and development of long-acting injectable (LAI) formulations of atypical antipsychotics in order to improve patient compliance, a notable unmet need.

However, Christos Michaelides, Ph.D., the Analyst covering Neurology and Ophthalmology, notes: “While schizophrenia market growth will primarily be driven by the arrival of late-stage pipeline products, such as Minerva’s MIN-101 and Intra-Cellular Therapies’ ITI-007, both of which are directed towards the treatment of negative symptoms associated with schizophrenia, these symptoms will remain a significant unmet need in the space.”

Negative symptoms are conceptualized as an absence or diminution of normal emotional responses or thought processes, and include those such as apathy or asociality. Positive symptoms, on the other hand, are described as those that healthy individuals would not experience, including the reality distortion symptoms of hallucinations and delusions, as well as disorganized thoughts and behaviors.

Michaelides continues: “According to the author's primary research, there is no drug that can treat the negative symptoms of schizophrenia currently available. Several studies have found that avolition, social withdrawal, flat emotional affect, and speech and movement dysfunction have a greater negative impact on the quality of life and dysfunctional outcomes of schizophrenic individuals than positive symptoms of the disease. A drug addressing this is therefore urgent.

“Drugs such as MIN-101 and ITI-007, would mean this unmet need is somewhat satisfied during the forecast period. However, the author believes that opportunity will remain for pharmaceutical companies to develop a drug that effectively targets negative symptoms of schizophrenia by 2025. Indeed, there is considerable R&D risk as past pipeline drugs that have attempted to target negative symptoms failed in clinical trials due to lack of efficacy.”

- Comments provided by Christos Michaelides, Ph.D., the Analyst covering Neurology and Ophthalmology.
- Information based on the report: PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025.
- This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by a team of industry experts.
Note: Product cover images may vary from those shown
5 of 6
  • Alexza Pharmaceuticals
  • Alkermes
  • Allergan
  • Almirall Prodesfarma
  • Astellas
  • AstraZeneca
  • Avanir Pharmaceuticals
  • Avineuro Pharmaceuticals
  • Braeburn Pharmaceuticals
  • Bristol-Myers Squibb
  • Dainippon Sumitomo/Sunovion
  • Eli Lilly
  • Epomedics
  • Ferrer
  • Gedeon Richter
  • HLS Therapeutics
  • Indivior
  • Intra-Cellular Therapies
  • Janssen
  • Laboratorios Farmaceuticos Rovi
  • Lundbeck
  • Meiji Seika
  • Merck & Co.
  • Minerva Neurosciences
  • Mitsubishi Tanabe Pharma
  • Neurocrine Biosciences
  • Nitto Denko Corporation
  • Novartis
  • Otsuka
  • Pfizer
  • Sandoz
  • Sanofi
  • SyneuRx
  • Takeda
  • Teva Pharmaceutical
  • Titan Pharmaceutical
  • Vanda Pharmaceuticals
  • Yoshitomi Yakuhin Corporation
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll